Aperio Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Aperio Group’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,601	Closed	-$43K	–	2876
2019 Q2	$43K	Buy	+3,601	New	+$38.7K	﹤0.01%	2564

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Aperio Group's CNCE Position: Q3 2019 in Review

Aperio Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2019, closing a stake of 3,601 shares — an estimated $43K sold.

Aperio Group first reported a position in CNCE in Q2 2019 and held it in 1 quarter. The position peaked at $43K in Q2 2019. 80 funds tracked by Wall St. Rank hold CNCE as of Q3 2019.

Aperio Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 3,601 Concert Pharmaceuticals, Inc. shares in Q3 2019, an estimated $43K.
Aperio Group first reported a position in Concert Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
Aperio Group's Concert Pharmaceuticals, Inc. position peaked at $43K in Q2 2019.
80 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.